Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study.
Bile acids
Cholestasis
Cholestatic liver failure
Critically ill patients
Cytosorb®
Mass spectrometry
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
14
06
2023
accepted:
27
09
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
The release of toxic bile acids (BAs) in the blood of critically ill patients with cholestatic liver dysfunction might lead to the damage of various organs. Their extracorporeal elimination using the cytokine adsorber Cytosorb The prospective Cyto-SOVLE study (NCT04913298) included 20 intensive care patients with cholestatic liver dysfunction, continuous kidney replacement therapy, total bilirubin concentration > 10 mg/dl and the application of CS into the dialysis circuit. Bilirubin and different BAs were measured pre- and post-CS at defined timepoints (10 min, 1, 3, 6, and 12 h after initiation). Relative reduction (RR, %) was calculated with: [Formula: see text]. The median RR for total and conjugated bilirubin after initiation was - 31.8% and - 30.3%, respectively, and decreased to - 4.5% and - 4.8% after 6 h. A high initial RR was observed for the toxic BAs GCA (- 97.4%), TCA (- 94.9%), GCDCA (- 82.5%), and TCDCA (- 86.0%), decreasing after 6 h to - 32.9%, - 32.7%, - 12.8%, and - 14.3%, respectively. The protective hydrophilic BAs showed a comparable RR after initiation (UDCA: - 77.7%, GUDCA: - 83.0%, TUDCA: - 91.3%) dropping after 6 h to - 7.4%, - 8.5%, and - 12.5%, respectively. Cytosorb
Sections du résumé
BACKGROUND
BACKGROUND
The release of toxic bile acids (BAs) in the blood of critically ill patients with cholestatic liver dysfunction might lead to the damage of various organs. Their extracorporeal elimination using the cytokine adsorber Cytosorb
METHODS
METHODS
The prospective Cyto-SOVLE study (NCT04913298) included 20 intensive care patients with cholestatic liver dysfunction, continuous kidney replacement therapy, total bilirubin concentration > 10 mg/dl and the application of CS into the dialysis circuit. Bilirubin and different BAs were measured pre- and post-CS at defined timepoints (10 min, 1, 3, 6, and 12 h after initiation). Relative reduction (RR, %) was calculated with: [Formula: see text].
RESULTS
RESULTS
The median RR for total and conjugated bilirubin after initiation was - 31.8% and - 30.3%, respectively, and decreased to - 4.5% and - 4.8% after 6 h. A high initial RR was observed for the toxic BAs GCA (- 97.4%), TCA (- 94.9%), GCDCA (- 82.5%), and TCDCA (- 86.0%), decreasing after 6 h to - 32.9%, - 32.7%, - 12.8%, and - 14.3%, respectively. The protective hydrophilic BAs showed a comparable RR after initiation (UDCA: - 77.7%, GUDCA: - 83.0%, TUDCA: - 91.3%) dropping after 6 h to - 7.4%, - 8.5%, and - 12.5%, respectively.
CONCLUSIONS
CONCLUSIONS
Cytosorb
Identifiants
pubmed: 37943350
doi: 10.1186/s13613-023-01198-7
pii: 10.1186/s13613-023-01198-7
pmc: PMC10635921
doi:
Banques de données
ClinicalTrials.gov
['NCT04913298']
Types de publication
Journal Article
Langues
eng
Pagination
110Subventions
Organisme : Else Kröner-Fresenius-Stiftung
ID : 2021_EKEA.101
Informations de copyright
© 2023. The Author(s).
Références
Intensive Care Med. 2019 Feb;45(2):236-239
pubmed: 30446798
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
PLoS One. 2021 Aug 5;16(8):e0255230
pubmed: 34351969
J Nephrol. 2021 Feb;34(1):77-88
pubmed: 32710265
Int J Artif Organs. 2022 Oct;45(10):878-882
pubmed: 35918853
Hepatology. 2019 Dec;70(6):2204-2215
pubmed: 31215660
World J Gastroenterol. 2009 Apr 14;15(14):1677-89
pubmed: 19360911
Chest. 2018 Mar;153(3):733-743
pubmed: 28847548
J Artif Organs. 2022 Sep;25(3):270-273
pubmed: 35038050
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
Crit Care. 2022 Sep 26;26(1):289
pubmed: 36163253
Trials. 2022 Apr 15;23(1):319
pubmed: 35428345
Clin Infect Dis. 2023 Feb 8;76(3):e179-e187
pubmed: 35809032
Blood Purif. 2022;51(3):243-250
pubmed: 34139706
Blood Purif. 2021;50(1):119-128
pubmed: 32615564
Adv Exp Med Biol. 2021;1275:229-258
pubmed: 33539018
Anesthesiology. 2012 Oct;117(4):898-904
pubmed: 22854981
Mol Aspects Med. 2017 Aug;56:45-53
pubmed: 28606651
Handb Exp Pharmacol. 2019;256:237-264
pubmed: 31236688
Am J Physiol Lung Cell Mol Physiol. 2022 Jul 1;323(1):L93-L106
pubmed: 35797724
J Community Hosp Intern Med Perspect. 2022 Jul 04;12(4):43-48
pubmed: 36262903
Biomolecules. 2018 Nov 27;8(4):
pubmed: 30486474
Sci Rep. 2021 May 13;11(1):10190
pubmed: 33986443
Intensive Care Med. 2022 Oct;48(10):1352-1367
pubmed: 36066598
Cureus. 2022 Mar 29;14(3):e23606
pubmed: 35505725
Intensive Care Med. 2021 Nov;47(11):1332-1333
pubmed: 34519848
Scand J Gastroenterol. 2022 Mar;57(3):311-318
pubmed: 34846975
Intensive Care Med. 2023 Mar;49(3):360-362
pubmed: 36763124
Gene Expr. 2018 May 18;18(2):71-87
pubmed: 29325602
Crit Care Med. 2007 Apr;35(4):1099-104
pubmed: 17334250